Evaluation of Heterozygous Deletion of TP53 Gene in Pleural Fluid Samples: A Case Series of 11 Patients

Simple item page
dc.contributor.authorDirican, N
dc.contributor.authorBagci, Ö
dc.contributor.authorUz, E
dc.contributor.authorOzturk, Ö
dc.contributor.authorBircan, HA
dc.contributor.authorDirican, A
dc.date.accessioned2024-07-18T12:00:13Z
dc.date.available2024-07-18T12:00:13Z
dc.description.abstractWe described heterozygous deletion of tumor protein 53 (TP53) gene in 11 patients including 2 patients with non- malignant diseases (pneumonia) and 9 patients with malignant diseases [including small cell lung cancer (n = 3), non-small cell lung carcinoma (n = 4), non-Hodgkin's lymphoma (n= 1), and gastric carcinoma (n= 1)]. Chromosomal aberrant status was analyzed by fluorescence in situ hybridization with centromere specific and 17p13.1 locus specific probes. In 3 of 9 cancer patients we did not find malignant pleural effusion with histological examination and/or closed pleural biopsy. Heterozygous deletion of TP53 gene was found to be significantly higher in patients with malignant disease when compared to the patients with benign pleural fluid. As a result, we suggest that heterozygous deletion of TP53 may have indicator value for malignancy; however further studies are warranted to confirm this suggestion in large patient cohorts.
dc.identifier.issn1309-0720
dc.identifier.other1309-2014
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/7565
dc.language.isoEnglish
dc.publisherDERMAN MEDICAL PUBL
dc.subjectIN-SITU HYBRIDIZATION
dc.subjectCANCER
dc.subjectCHROMOSOME-9
dc.subjectMECHANISMS
dc.subjectEFFUSIONS
dc.subjectFREQUENCY
dc.subjectANTIGEN
dc.subjectMARKER
dc.subjectTUMORS
dc.subjectFISH
dc.titleEvaluation of Heterozygous Deletion of TP53 Gene in Pleural Fluid Samples: A Case Series of 11 Patients
dc.typeArticle

Files

Collections

Web of Science Koleksiyonu